Health Science seeks botantical patents

- Last updated on GMT

Related tags: Medicine, Pharmacology, Pharmacy

Nutraceutical ingredients supplier Health Sciences Group is to push
forward patents for its new CoCare product line born from the
recent synergy with Quality Botanical Ingredients.

Nutraceutical ingredients supplier Health Sciences Group is to push forward patents for its new CoCare product line born from the recent synergy with Quality Botanical Ingredients.

Earlier this year the Health Sciences Group acquired bulk botanical materials and nutritional ingredients company QBI - a move which dramatically lifted profits and sales of the group for the second quarter ended June 30, 2003.

In a statement this week the company said that its BioSelect division is seeking intellectual property protection for six products from the new CoCare product line, developed using the ' formulating expertise of its Quality Botanical Ingredients division, a cryogenic processor of 500 different herbs and botanicals'.

The line includes formulations to treat nasal and sinus congestion, acid reflux, cough reflex, allergy and cold relief and pain relief.

Fred E. Tannous, CEO and co-chairman of the Health Sciences Group - that recently purchased bulk botanical materials and ingredients company Quality Botanical Ingredients - highlighted 'the growing interest in herbal remedies by physicians and consumers, and a steady flow of new research,' as a key motivation behind the patent push.

"BioSelect's CoCare products will combine generic OTC pharmaceutical medications with complementary nutraceutical ingredients, providing more complete treatments for common ailments,"​ he commented.

The company stresssed the advantage that herbs and botanical ingredients have in complementing 'OTC products by increasing their potency, broadening their effectiveness and protecting the body from otherwise harmful side-effects.'

" The CoCare line is expected to bring these elements together in a commercially attractive fashion,"​ said Dr. Daniel Gelber, director of research & development at BioSelect.

"Since each CoCare product will feature the health claims of a well-known OTC pharmaceutical ingredient, these combination products should benefit from an established customer base,"​ added Bill Glaser, president and co-chairman of the Health Sciences Group.

BioSelect is looking to license the production and marketing of its CoCare product line to third parties.

Related topics: Regulation

Related news

Show more

Follow us

Products

View more

Webinars